Why the study?
Does tamoxifen improve cardiovascular risk factors in postmenopausal women with breast cancer over 5 years of treatment?
Population
62 disease-free, axillary node-negative postmenopausal breast cancer patients
Comparison
Tamoxifen therapy for 5 years vs No-tamoxifen regimen for 5 years
Design
RCT, Randomly assigned, Placebo-controlled (initial 2-year study)
Follow-up
5 years
Authors
Loading...
Tamoxifen sustains lipid improvements over 5 years in breast cancer patients; extends 2-year data and reinforces observed MI reductions.
Does tamoxifen improve cardiovascular risk factors in postmenopausal women with breast cancer over 5 years of treatment?
Tamoxifen therapy for 5 years in postmenopausal women with breast cancer is associated with persistent favorable changes in lipid and lipoprotein profiles.
Love et al. (1994) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: